Related Experiment Video
Updated: Oct 13, 2026
The Intra-Aortic Balloon Pump
Published on: February 5, 2021
Economic impact of preoperative intraaortic balloon pump therapy in high-risk coronary patients
J T Christenson1, F Simonet, M Schmuziger
1Department of Cardiovascular Surgery, Hôpital de la Tour, Meyrin-Geneva, Switzerland. jtchristenson@hotmail.com
Insights
Preoperative intraaortic balloon pump therapy significantly reduces costs for high-risk coronary artery bypass graft surgery. This therapy offers substantial savings, making it a cost-beneficial option for these patients.
Area of Science:
- Cardiovascular Surgery
- Health Economics
- Medical Technology Assessment
Background:
- Preoperative intraaortic balloon pump (IABP) therapy is known to be effective in high-risk coronary patients.
- The economic implications of using IABP in this patient group require detailed investigation.
Purpose of the Study:
- To conduct a comprehensive cost analysis of preoperative intraaortic balloon pump therapy in high-risk coronary artery bypass graft (CABG) operations.
- To compare the total hospital costs between patients receiving IABP and a control group.
Main Methods:
- Pooled data from two randomized studies and 144 consecutive low-risk CABG operations were analyzed.
- Detailed cost analysis was performed using hospital finance department data.
- Costs for high-risk CABG patients with and without preoperative IABP were compared to a control group.
Main Results:
- High-risk CABG without IABP cost 65,892 Swiss francs, while with IABP, it cost 41,948 Swiss francs.
- Low-risk CABG operations cost 35,335 Swiss francs.
- The use of IABP in high-risk patients resulted in a significant cost reduction (p = 0.0015).
Conclusions:
- Preoperative intraaortic balloon pump therapy is a significantly cost-beneficial intervention for high-risk coronary patients undergoing CABG.
- This therapy leads to an average saving of 24,000 Swiss francs per patient, representing a 36% reduction in total hospital costs.
Background:
The efficacy of preoperative intraaortic balloon pump therapy in high-risk coronary patients has been demonstrated earlier.
Methods:
This study investigates the economic aspect by a detailed cost analysis of pooled information from two previously published randomized studies and 144 consecutive low-risk coronary artery bypass graft operations. Costs for patients receiving preoperative intraaortic balloon pump therapy before aortic cross-clamping (n = 62) were compared to those in a control group (n = 50). Detailed cost analysis was based on data provided by the hospital finance department.
Results:
The total hospital costs were as follows: low-risk coronary artery bypass graft operations cost 35,335+/-1,694 Swiss francs ($23,400+/-$1,121); high-risk coronary artery bypass graft without preoperative intraaortic balloon pump therapy cost 65,892+/-31,719 Swiss francs ($43,637+/-$21,006); and high risk coronary artery bypass graft with preoperative intraaortic balloon pump therapy cost 41,948+/-10,379 Swiss francs ($27,780+/-$6,874) (p = 0.0015). There were no significant differences in average cost among the preoperative intraaortic balloon pump therapy subgroups.
Conclusions:
Preoperative intraaortic balloon pump therapy in high risk coronary patients is significantly cost-beneficial, With an average saving of 24,000 Swiss francs ($16,000) on the total hospital cost, a 36% cost reduction.
More Related Videos
07:39Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
Published on: August 16, 2021
05:25Surgical Porcine Model of Chronic Myocardial Ischemia Treated by Exosome-laden Collagen Patch and Off-pump Coronary Artery Bypass Graft
Published on: September 15, 2023
